Always verify pricing and state availability on the provider's website before signing up.How our reviews work →
Get Thin MD vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
7.9
Get Thin MD
Best for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available★★★★☆4
Starting at $169/mo
CompoundedSemaglutideTirzepatideBrand
Visit Get Thin MD →7.9
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launch★★★★☆4
Starting at $149/mo
FoundayoSemaglutideTirzepatideWegovy
Visit Ro →Side-by-Side Comparison
| Feature | Get Thin MD | Ro |
|---|---|---|
| Overall Score | 7.9/10 | 7.9/10 |
| Starting Price | $169/mo | ✓$149/mo |
| Editorial Rating | 4 ★ /5 | 4 ★ /5 |
| Features | 7 features | 7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Get Thin MD
Pros
- ✓3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
- ✓Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
- ✓Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
- ✓Nationwide availability with async evaluation — no in-person visit required
- ✓Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
- ✓Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."
Cons
- ✗Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
- ✗Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
- ✗State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
- ✗Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
- ✗Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Both Get Thin MD and Ro score equally well overall — the right choice depends on your priorities. Choose Get Thin MD if you want lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available, or Ro if broadest GLP-1 formulary including Foundayo on day-one of launch matters most to you.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.